Data / Drug companies / Patheon Inc.
Patheon Inc.: 77 products in the FDA NDC directory, labeler code 63285
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Inc. (labeler code 63285) lists 77 products in the FDA National Drug Code Directory. By type: 77 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on July 22, 2026.
The request: Watch Patheon Inc. (FDA labeler code 63285): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 63285
- Products in commercial distribution
- 77
- Packages
- 89
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 9
- Started marketing in the last 12 months
- 11
- Earliest marketing start
- December 24, 1998
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 77 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 77 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 30 | 39% |
| Tablet | 17 | 22.1% |
| Capsule | 11 | 14.3% |
| Kit | 9 | 11.7% |
| Tablet, coated | 8 | 10.4% |
| Tablet, orally disintegrating, delayed release | 1 | 1.3% |
| Granule, for suspension | 1 | 1.3% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zidesamtinib | 63285-936 | Tablet, film coated | Drugs for further processing | July 22, 2026 |
| Zidesamtinib | 63285-935 | Tablet, film coated | Drugs for further processing | July 22, 2026 |
| Avapritinib | 63285-957 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Avapritinib | 63285-956 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Avapritinib | 63285-955 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Milsaperidone | 63285-940 | Kit | Drugs for further processing | April 5, 2026 |
| Milsaperidone | 63285-937 | Kit | Drugs for further processing | March 31, 2026 |
| Milsaperidone | 63285-939 | Kit | Drugs for further processing | March 30, 2026 |
| Milsaperidone | 63285-938 | Kit | Drugs for further processing | March 30, 2026 |
| Repotrectinib | 63285-934 | Capsule | Drugs for further processing | February 4, 2026 |
| Ziftomenib | 63285-928 | Capsule | Drugs for further processing | November 13, 2025 |
| Norethindrone acetate/ethinyl estradiol | 63285-927 | Tablet, orally disintegrating, delayed release | Drugs for further processing | May 27, 2025 |
| Norethindrone acetate/ethinyl estradiol | 63285-926 | Kit | Drugs for further processing | May 27, 2025 |
| Iloperidone | 63285-923 | Kit | Drugs for further processing | October 5, 2024 |
| Iloperidone | 63285-924 | Kit | Drugs for further processing | May 27, 2024 |
| Repotrectinib | 63285-905 | Capsule | Drugs for further processing | November 15, 2023 |
| Emtricitabine and tenofovir alafenamide fumarate | 63285-933 | Tablet | Drugs for further processing | March 28, 2023 |
| Relugolix tablet, film coated | 63285-904 | Tablet, film coated | Drugs for further processing | January 27, 2023 |
| Adagrasib | 63285-894 | Tablet, coated | Drugs for further processing | December 12, 2022 |
| Deucravacitinib | 63285-893 | Tablet, film coated | Drugs for further processing | September 10, 2022 |
| Mavacamten | 63285-877 | Capsule | Drugs for further processing | April 28, 2022 |
| Mavacamten | 63285-876 | Capsule | Drugs for further processing | April 28, 2022 |
| Mavacamten | 63285-875 | Capsule | Drugs for further processing | April 28, 2022 |
| Mavacamten | 63285-874 | Capsule | Drugs for further processing | April 28, 2022 |
| Nirmatrelvir | 63285-892 | Tablet, film coated | Drugs for further processing | December 22, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.